



Discover how CSAN® (PrCLOZARIL® Support and Assistance Network) has been supporting patient and healthcare teams' experiences for OVER 30 YEARS1

When you choose to prescribe CLOZARIL®



Your patients are taken care of right from the start of their treatment journey by CSAN®, your support and assistance network.

CLOZARIL® (clozapine) tablet is indicated in the management of symptoms of treatment-resistant schizophrenia.2

PATIENT SUPPORT PROGRAM

Offering tailored services supported by a team of experts

- Supporting you 24/7/365 (even on statutory holidays) with any required assistance - including use of the CSAN Patient Care Portal®
- Access to bilingual specialty consultants who can help guide a customized course of action throughout each patient's CLOZARIL® treatment journey:
 - Psychiatrists, cardiologists, registered nurse educators, a hematologist, and a nutritionist
- CSAN® Pronto®, a capillary point-of-care device, is integrated within CSAN® to facilitate mandatory bloodwork requirements
- And much more to discover

Learn more about how CSAN® can support you with a wide range of services in the management of your CLOZARIL®-treated patients:



1-800-267-2726 1-800-267-CSAN (2726)



1-800-465-1312

CSAN®'s tailored services are meant for your patients' individual needs.



Register your patients with treatment-resistant schizophrenia using the CSAN® Patient Registration Form



Please consult the CLOZARIL® Product Monograph at http://www.hlstherapeutics.com/wp-content/uploads/monograph_pdf/HLS-Clozarii-PM-E.pdf for important information on contraindications, warnings, precautions, adverse reactions, drunteractions, dosing, and conditions of clinical use. The Product Monograph is also available by calling 1-800-267-2726.

October 2022 CA-CL-00068-EN

References:

- Data on file. HLS Therapeutics Inc.
 CLOZARIL® Product Monograph. HLS Therapeutics Inc. May 31, 2022.











HLS Therapeutics Inc. 10 Carlson Court, Suite 701 Etobicoke, Ontario M9W 6L2 www.hlstherapeutics.com

CLOZARIL®, CSAN® and CSAN Patient Care Portal® + Design are all registered trademarks of Novartis AG. Pronto® is a registered trademark of HLS Therapeutics Inc. All rights reserved. © Copyright 2022 HLS Therapeutics Inc.